All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Extracellular circulating Tat can be endocytosed by surrounding uninfected cells via the binding to several surface receptors such as CD26, CXCR4, heparan sulfate proteoglycans (HSPG) or LDLR. Neurons are rarely infected, but they internalize Tat via their LDLR. Through its interaction with nuclear HATs, Tat is potentially able to control the acetylation-dependent cellular gene expression. Modulates the expression of many cellular genes involved in cell survival, proliferation or in coding for cytokines or cytokine receptors. Tat plays a role in T-cell and neurons apoptosis. Tat induced neurotoxicity and apoptosis probably contribute to neuroAIDS.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-L108 | Human anti-tat (ITKGLGISYGR) T Cell Receptor, pGMT7 | HIV | Human | ITKGLGISYGR | HLA-A68 | retroviral vector | ||
TCR-L107Z | Human anti-Tat (aa39-49) T cell receptor, pCDTCR1 | HIV | Human | ITKALGISYGR | HLA-A68 | Lentiviral | ||
TCR-C243Z | Human anti-Tat T cell receptor (c23), pCDTCR1 | HIV-1 | c23 | Human | ITKGLGISYGR | HLA-A68 | Lentiviral |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION